AI method reveals 17 existing drugs that may fight against COVID-19
Scientists used artificial intelligence to identify 17 existing drugs that could kill SARS-CoV-2 in cells, including a dietary supplement.
List view / Grid view
Scientists used artificial intelligence to identify 17 existing drugs that could kill SARS-CoV-2 in cells, including a dietary supplement.
Researchers have used fruit fly larvae to explore how alpha-synuclein impacts the mitochondria, advancing the study of Parkinson’s disease.
Researchers have created a new method to quantify protein droplets involved in neurodegenerative diseases, enhancing the study of treatments.
US researchers have identified new biomarkers that can detect early changes in the eye that can lead to diabetes-related blindness.
Accelerate the discovery process of new drugs and targets with a better understanding of the metabolome and lipidome during drug development.
The cell painting assay uses up to six fluorescent dyes to label and visualize a variety of subcellular structures at the single cell level.
New insights into lung squamous cell carcinoma (LSCC) have emerged from a proteogenomic study, leading to the identification of potential drug targets.
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
A US team has designed a high-quality, high-speed imaging system that could lead to new understandings of complex tissue specimens.
14 July 2021 | By Analytik Jena
In this on-demand webinar, based on field experiences with our research partners, Analytik Jena provides an overview of application demands for a reliable sample preparation automation – from a small and easy-to-use workstation, to a fully automated integration solution by Analytik Jena.
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.